Knowledge Exchange & Policy Influence

At the Centre for Global Epilepsy, we turn research into action through publishing, policy advocacy, and building key partnerships. By producing reports, hosting funder summits, and collaborating with stakeholders, we shape policies and drive progress in epilepsy care.

Centre for Global Epilepsy Journal Publications

  1. Epilepsy in Low- to Middle-Income Countries. Current Opinion in Neurology. Sen, A., Newton, C. R., & Ngwende, G. (2025) 
    This review highlights opportunities to improve epilepsy care in low- and middle-income countries (LMICs), where diagnostic and treatment gaps persist. Strategies such as implementing the WHO IGAP, using the Epilepsy Diagnostic Companion, and leveraging innovations like 3D printable EEG headsets offer practical solutions. Expanded access to antiseizure medications and the potential for epilepsy surgery also provide promising options. The review stresses the need for bidirectional learning to support epilepsy care in both LMICs and high-income settings.
     
  2. Classification of the Epilepsies: Evolving with Time, Science, and Knowledge. Practical Neurology. Sen, A., & Zuberi, S. M. (2025) 
    The article explores the challenges and nuances in classifying seizures and epilepsy. It outlines the ILAE’s 2017 classification, which categorizes seizures into focal, generalised, and unknown onset types, with updates in 2024 suggesting further modifications. Despite these classification systems, the article emphasizes that understanding a patient's history, EEG results, and ongoing investigations is key to accurate diagnosis, as seizures often present in ways that don’t fit neatly into these categories. The article addresses the importance of a holistic approach, revisiting cases, and continuously reassessing diagnoses to ensure the best patient outcomes. 
     
  3. Equitable Access to Levetiracetam for People with Epilepsy. The Lancet Neurology. Sen, A., Chowdhary, N., Hallab, A., Romoli, M., Cross, J. H., & Cappello, B. (2024) 
    This paper addresses the global challenge of ensuring equitable access to levetiracetam, a key anti-seizure medication recently included in the 2023 WHO Model Lists of Essential Medicines. It highlights the persistent barriers in low- and middle-income countries (LMICs), including gaps in policy, affordability, and healthcare provider training. The paper stresses the need for coordinated global action to update national essential medicines lists, improve the availability of generic medications, and ensure that healthcare systems are equipped to deliver these treatments effectively and affordably to those who need them most.